Richard E. Chipkin

President and Chief Executive Officer at Psyadon Pharmaceuticals, Inc.

20451 Seneca Meadows Parkway, Germantown, Maryland, United States
Psyadon Pharmaceuticals, Inc.
HQ Phone:
(301) 919-2020
Wrong Richard Chipkin?

Last Updated 12/6/2017

General Information


Ph.D.  - Pharmacology , Medical College of Virginia

undergraduate degree  - Pharmacology , State University of New York at Albany


President and Chief Executive Officer  - Psychiatric Genomics , Inc.

Position, Global Business Development Group  - Schering-Plough Corporation

Board Member  - Tech Council of Maryland

Board Member  - Technology Vision Group LLC

Division Board of Directors Member  - MdBio , Inc.

Web References  

Psyadon Pharmaceuticals Home Page

Dr. Richard E. Chipkin, PhD, President and CEO
Dr. Chipkin has more than 20 years experience at both biotech and big pharmaceutical companies. Most recently, he was President and CEO of Psychiatric Genomics. While there, he raised two rounds of venture capital financing, re-organized the company, and negotiated multiple academic licenses. Prior to that, he worked at Schering-Plough Corporation in the Global Business Development Group, where he was responsible for licensing and acquisition in multiple therapeutic areas. In this capacity, Dr. Chipkin negotiated several multi-million dollar research & development and development/marketing deals, including the license for INTEGRILIN, currently a $250M/year product. Earlier in his career at Schering-Plough, he held positions in both preclinical and clinical neuropharmacology research. Among his accomplishments in the research arena were the discovery of novel analgesic and antipsychotic drugs, including the identification and human testing of ecopipam -- the worlds first selective D1 antagonist. Dr. Chipkin received his undergraduate degree from the State University of New York at Albany and his PhD in Pharmacology from the Medical College of Virginia. He did post-doctoral work at the University of Colorado Medical Center.

Read More
Tourette Syndrome Association and Psyadon Pharmaceuticals to collaborate on #OrphanDrug trial - Orphan Drugs

Richard Chipkin, President and CEO of Psyadon, stated, "We are honored to be selected as the first company the TSA has collaborated with on a clinical drug study.

Read More
Paragon Bioservices CEO Elected to the MdBio Division Board of Directors | UM BioPark

Richard E. Chipkin, Ph.D., President and CEO, Psyadon Pharmaceuticals

Read More

Browse ZoomInfo’s Directories